Literature DB >> 7386307

Anti-inflammatory activity of a dermally applied copper salicylate preparation (Alcusal).

W R Walker, S J Beveridge, M W Whitehouse.   

Abstract

In rats, dermal (dorsum) application of an ethanolic copper salicylate complex (ECS) in ethanol with glycerol (Alcusal) effectively suppressed established polyarthritis, carrageenan-induced paw oedema and the inflammatory response to hydroxylapatite microcrystals. These responses appear to be due to some degree of synergism between the copper(II) and salicylate, i.e. not solely due to either species alone. Evidence for transdermal absorption of 64Cu from 64Cu-ECS is provided. Some safety aspects of this novel drug are discussed.

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7386307     DOI： 10.1007/bf02024177

Source DB:  PubMed          Journal:  Agents Actions        ISSN： 0065-4299


  29 in total

Review 1.  The biological actions of endouterine copper.

Authors:  J C Middleton; M Kennedy
Journal:  Contraception       Date:  1975-02       Impact factor: 3.375

2.  Evaluation of copper complexes as potential anti-arthritic drugs.

Authors:  J R Sorenson
Journal:  J Pharm Pharmacol       Date:  1977-07       Impact factor: 3.765

3.  Some copper coordination compounds and their antiinflammatory and antiulcer activities.

Authors:  J R Sorenson
Journal:  Inflammation       Date:  1976-06       Impact factor: 4.092

4.  Reactivity of antiinflammatory and superoxide dismutase active Cu(II)-salicylates.

Authors:  U Weser; C Richter; A Wendel; M Younes
Journal:  Bioinorg Chem       Date:  1978

5.  An investigation of the therapeutic value of the 'copper bracelet'-dermal assimilation of copper in arthritic/rheumatoid conditions.

Authors:  W R Walker; D M Keats
Journal:  Agents Actions       Date:  1976-07

6.  Pulse radiolytically generated superoxide and Cu(II)-salicylates.

Authors:  M Younes; E Lengfelder; S Zienau; U Weser
Journal:  Biochem Biophys Res Commun       Date:  1978-03-30       Impact factor: 3.575

7.  Treatment of rheumatoid and degenerative diseases with copper complexes: a review with emphasis on copper-salicylate.

Authors:  J R Sorenson; W Hangarter
Journal:  Inflammation       Date:  1977-09       Impact factor: 4.092

Review 8.  Some biochemical and pharmacological properties of anti-inflammatory drugs.

Authors:  M W Whitehouse
Journal:  Fortschr Arzneimittelforsch       Date:  1965

9.  A comparison of the anti-inflammatory effects of copper aspirinate and other copper salts in the rat and guinea pig.

Authors:  A J Lewis
Journal:  Agents Actions       Date:  1978-04

10.  Experimental inflammation induced by naturally occurring microcrystalline calcium salts.

Authors:  C W Denko; M W Whitehouse
Journal:  J Rheumatol       Date:  1976-03       Impact factor: 4.666
View more
  5 in total

1.  Anti-inflammatory properties of copper implants in the rat paw edema: a preliminary study.

Authors:  H H Dollwet; S P Schmidt; R E Seeman
Journal:  Agents Actions       Date:  1981-12

2.  Orally active antioxidative copper(II) aspirinate: synthesis, structure characterization, superoxide scavenging activity, and in vitro and in vivo antioxidative evaluations.

Authors:  T Fujimori; S Yamada; H Yasui; H Sakurai; Y In; T Ishida
Journal:  J Biol Inorg Chem       Date:  2005-10-28       Impact factor: 3.358

3.  Biodistribution of 64Cu in rats after topical application of two lipophilic anti-inflammatory Cu(II) formulations.

Authors:  S J Beveridge; B Boettcher; W R Walker; M W Whitehouse
Journal:  Agents Actions       Date:  1984-02

4.  Lipophilic copper(II) formulations: some correlations between their composition and anti-inflammatory/anti-arthritic activity when applied to the skin of rats.

Authors:  S J Beveridge; M W Whitehouse; W R Walker
Journal:  Agents Actions       Date:  1982-04

5.  Biodistribution of 64Cu in inflamed rats following administration of two anti-inflammatory copper complexes.

Authors:  S J Beveridge; I R Garrett; M W Whitehouse; B Vernon-Roberts; P M Brooks
Journal:  Agents Actions       Date:  1985-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.